Relation of Fractional Flow Reserve After Drug-Eluting Stent Implantation to One-Year Outcomes
- Affiliated Author(s)
- 남창욱; 허승호; 조윤경; 박형섭; 윤혁준; 김형섭; 김윤년; 김권배; 정인성
- Alternative Author(s)
- Nam, Chang Wook; Hur, Seung Ho; Cho, Yun Kyeong; Park, Hyoung Seob; Yoon, Hyuck Jun; Kim, Hyung Seop; Kim, Yoon Nyun; Kim, Kwon Bae; Chung, In Sung
- Journal Title
- American Journal of Cardiology
- ISSN
- 0002-9149
- Issued Date
- 2011
- Abstract
- Patients still present with drug-eluting stent (DES) failure despite an angiographically
successful implantation. The aim of the present study was to investigate the relation
between the fractional flow reserve (FFR) measured after DES implantation and the
clinical outcomes at 1 year. A total of 80 patients (mean age 62 years, 74% men, 99 DESs)
underwent coronary pressure measurement at maximum hyperemia after successful DES
implantation. The composite of major adverse cardiac events (MACE), including death,
myocardial infarction, and ischemia-driven target vessel revascularization was evaluated at
1 year. The patients were divided into 2 groups (low-FFR group, FFR <0.90 and high-FFR
group, FFR >0.90) according to the median FFR. The mean poststent percent diameter
stenosis was 11 5% in the low-FFR group and 12 3% in the high-FFR group (p 0.31).
Left anterior descending coronary artery lesions were more frequent in the low-FFR group
than in the high-FFR group (82% vs 55%, p 0.02). The mean stent length was greater in
the low-FFR group than in the high-FFR group (38 18 vs 28 13 mm, p 0.01). Six
cases (7.5%) of MACE occurred during the 1-year follow-up. The rate of MACE was
12.5% in the low-FFR group and 2.5% in the high-FFR group (p <0.01). Receiver
operating characteristic curves revealed 0.90 as the best cutoff of FFR after DES
implantation for the prediction of 1-year MACE. In conclusion, a poststent FFR of
<0.90 correlated with a greater adverse event rate at 1 year. © 2011 Published by
Elsevier Inc. (Am J Cardiol 2011;107:1763–1767)
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.